SCHEMBL18745372

SCHEMBL18745372

CNC(=O)[C@@H]1CCN(C(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.41
NOTUM Q6P988 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAP4K4 O95819 1/20 0.35
CHRNB2 P17787 2/20 0.35
CHRNA4 P43681 2/20 0.35
CHRNA7 P36544 1/20 0.35
LMNA P02545 1/20 0.35
PDK2 Q15119 2/20 0.34
ATM Q13315 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRM1 P11229 1/20 0.33
DPP4 P27487 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18626574 1.00 BCHE (0.41) BCHENOTUMRXFP1SMN1; SMN2ALDH1A1
SCHEMBL24777622 0.89 BCHE (0.49) BCHENOTUMRXFP1SMN1; SMN2ALDH1A1
SCHEMBL8016072 0.89 RXFP1 (0.43) BCHENOTUMRXFP1SMN1; SMN2ALDH1A1
SCHEMBL20994692 0.84 ATM (0.42) BCHENOTUMRXFP1SMN1; SMN2ALDH1A1
SCHEMBL2146193 0.84 LMNA (0.45) SMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL21536052 0.83 BCHE (0.43) BCHENOTUMRXFP1SMN1; SMN2ALDH1A1
SCHEMBL18745367 0.82 ALDH1A1 (0.43) ALDH1A1LMNAMAPK1KMT2A
SCHEMBL18745375 0.81 BCHE (0.47) BCHERXFP1SMN1; SMN2ALDH1A1DPP4
SCHEMBL21569636 0.80 BCHE (0.45) BCHENOTUMRXFP1SMN1; SMN2ALDH1A1
SCHEMBL24109563 0.80 TSHR (0.37) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11498926-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2022-11-15 US disclosed
US-20210188872-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORTION 2021-06-24 US disclosed
US-10919912-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE HOLDINGS CORPORATION (US) 2021-02-16 US disclosed
US-20200131195-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION 2020-04-30 US disclosed
US-10464947-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE HOLDINGS CORPORATION (US) 2019-11-05 US disclosed
US-9624241-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2017-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131195-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 BCHE 3135/4885NOTUM 3538/4885RXFP1 3662/4885
US-20210188872-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 BCHE 3135/4885NOTUM 3538/4885RXFP1 3662/4885
US-11498926-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 BCHE 3135/4885NOTUM 3538/4885RXFP1 3662/4885
US-10464947-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 BCHE 3135/4885NOTUM 3538/4885RXFP1 3662/4885
US-10919912-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 BCHE 3135/4885NOTUM 3538/4885RXFP1 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.